放疗与 NK 细胞免疫治疗联合的进化双重束缚治疗用于前列腺癌

Evolution-informed therapies exploit evolutionary consequences of drug resistance to inhibit treatment resistance and prolong time to progression. One strategy, termed an evolutionary double-bind, uses an initial therapy to elicit a specific adaptive response by cancer cells, which is then selectively targeted by a follow-on therapy. Although the concept of an evolutionary double-bind has long been hypothesized in cancer, it has not been measured. Here, to our knowledge, we present the first example of a quantifiable double-bind: radiation therapy (RT) with natural killer (NK) cells. RT induces lethal double-strand DNA breaks, but cancer cells adapt. Although this increases resistance to DNA-damaging agents, it also enhances expression of NK cell ligands creating an obvious choice for a double-bind strategy. METHODS AND MATERIALS: We investigated this potential evolutionary double-bind through in vitro studies and evolution-based mathematical models. Using multiple prostate cancer cell lines, we evaluated surface and soluble NK ligand expression following RT. In vitro competition experiments were performed with an isogenic radiation-resistant cell line model. We introduced a two-population Lotka-Volterra competition model, consisting of radiation-sensitive and radiation-resistant populations modeling intrinsic growth rates with fixed carrying capacity and inter-specific competition terms.

Alterations in NK cell ligands resulted in a twofold increase in sensitivity to NK cell-mediated killing with selective targeting of RT-resistant cells. These dynamics were framed mathematically to quantify the double bind. RT alone slowed overall growth but strongly selected for RT-resistant cells. NK cell therapy alone suppressed the RT-resistant population, but with a surviving population of radiation-sensitive cells. Model simulation predicted that optimal tumor control would be achieved through initial RT followed by NK cells. Subsequent experiments confirmed the model prediction.

We conclude that RT and NK cell-based immunotherapy produce an evolutionary double-bind. This multidimensional approach addresses the immediate challenge of treatment resistance and lays the groundwork for the development of personalized treatment regimens tailored to the evolving dynamics of individual tumors. SIGNIFICANCE: Clinical experience demonstrates that prostate cancer has a remarkable capacity to evolve resistance to all currently available treatments resulting in progression and, ultimately, patient death. Resistance mechanisms often come at a fitness cost placing cells in a bind when competing with surrounding cells. A carefully chosen secondary drug can introduce a double-bind targeting the adaptive resistance mechanism. This manuscript provides the first direct experimental evidence quantifying an "evolutionary double-bind' in prostate cancer supporting the combination of DNA-damaging agents and NK cell-based immunotherapy in evolutionarily guided treatment designs. Our work is mathematically novel in that it extends Evolutionary Game Theory models and establishes an experimental-mathematical framework to quantify genuine evolutionary double binds applicable across cancer types and treatment modalities.